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HCV is mainly characterized by two major immunologic fingerprints, namely, escape of immune response in more than 80% of infected patients and production of autoantibodies in almost half of them.
Within the infected host, HCV exists as a quasispecies or a flock of related viral sequences. HCV can evolve rapidly as its replicative cycle yields 10 12 HCV particles per day in the liver, whereas in the serum the newly produced viral particles have an estimated halflife of about 3 hours. This high rate of virus production coupled with the lack of proofreading capacity of the HCV's NS5B RNA-dependent RNA polymerase lead to its rapid evolution and escape from immune recognition in each host. In addition, HCV profoundly deranges the functions of immune system. It deregulates both innate and adaptive antiviral response. It has been shown that HCV-encoded proteins subvert type I interferon (IFN) receptor signal transduction and the function of downstream IFN effector pathway. The virus decreases the ability of NK cells to promote dendritic cell maturation modifying antigen presentation and production of soluble mediators including IL-10 and IL-12. Resolution of HCV infection is mainly dependent on adaptive immunity and is associated with a robust and sustained specific T-cell response targeting multiple epitopes and intrahepatic IFN-γ production. Defective CD4 + T cells in both acute and chronic HCV infection lead to CD8 + T-cell exhaustion.
While HCV evolves under immunological pressure, the cellular immune response remains focused on viral sequences encountered early in the course of the infection. Indeed, humoral immune response seems more flexible in that the continued emergence of new antibody specificities sharply contrasts with the static T-cell response. Indubitable, interaction of HCV with B cells may promote favourable conditions for lymphocyte proliferation. Viral replicative intermediary was found in the B cell from patients with mixed cryoglobulinemia (MC), whereas no traces of HCV productive particles were demonstrable in HCV-infected individuals without cryoglobulin production, supporting the notion that HCV is not a genuine lymphotropic virus, but its entry and replication are largely dependent on host selective interactions. HCV binding to BCR triggers both the initiation of signaling cascade and internalization of the BCR and bound antigen into the cell. These interactions result in in vivo polyclonal activation and expansions of CD19 + CD5 + cells.
Extrahepatic disease manifestations, which include autoimmune phenomena and frank autoimmune and/or rheumatic diseases, may complicate the clinical features of chronic HCV infection and sometimes dominate its course in almost half of chronic HCV carriers. Possibly, progression to frank B-cell lymphoid malignancy may also be superposed as additional stochastic oncogenic event. However, there are many dark areas in the comprehension of several aspects of their pathogenetic mechanisms. The nature of the process during which B cells expand with preferential involvement of rheumatoid factor-(RF-) producing B cells is undefined. Whether B-cell clonal expansion of a particular specificity occurs as a result of distinct selection is not clear. The process of B-cell clonal expansion occurring in an environment 2 Clinical and Developmental Immunology favourable to the immortalization of one specific clone must be clarified. Predisposing factors for transforming events must be identified.
Against this background, it was felt that times were ripe to produce a state-of-the-art survey of the multifaceted pictures of HCV-related immune disorders. This special issue is therefore devoted to expand our knowledge on the features and mechanisms underlying the relationship between Bcell immune response and extrahepatic manifestations of chronic HCV infection. It comprises 16 review articles and 1 clinical study.
The paper by T. Himoto and T. Masaki is a general overview on HCV-related extrahepatic manifestations including cryoglobulinemia, Sjögren's syndrome, autoimmune thyroid disease, lichen planus, CREST syndrome, IFN-induced autoimmunity, and autoimmune cytopenia. 
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